Therma Bright gründet neues Unternehmen namens Torion Biosciences zur Entwicklung seines COVID-19 Antigen-Schnelltests, CoviSafe(TM)
Toronto, Ontario--(Newsfile Corp. - Donnerstag, 5. November 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma Bright" oder das "Unternehmen"), ein fortschrittliches Medizintechnikunternehmen, gibt die Gründung eines neuen Unternehmens mit dem Namen Torion Biosciences Inc. ("Torion") bekannt, das der Entwicklung, Lizenzierung und Vermarktung eines Antigen-Schnelltests zum Screening symptomatischer sowie asymptomatischer COVID-19-Infizierter bzw. -Verdachtspersonen dienen soll. Therma Bright...
2020-11-05 4:18 PM EST
Therma Bright Creates New Venture, Torion Biosciences to Develop its COVID-19 Rapid Antigen Test, CoviSafe(TM)
Toronto, Ontario--(Newsfile Corp. - November 4, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma Bright" or the "Company"), a progressive medical device technology company announces that it has created a new venture, called Torion Biosciences Inc. ("Torion") with a mandate to develop, license and commercialize a rapid antigen test for screening of both symptomatic and asymptomatic individuals, infected or suspected of being infected with the COVID-19 virus. Therma Bright will control 50% of...
2020-11-04 5:00 PM EST
Therma Bright and Orpheus Medica Advance CoviSafe(TM) Rapid Saliva Test to Formal Product Developmental Phase
Toronto, Ontario--(Newsfile Corp. - October 21, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, and its co-development partner, Orpheus Medica Inc. ("Orpheus") are pleased to announce the successful completion of the initial feasibility studies with its polypeptide detection candidates for CoviSafe™. Therma & Orpheus are also pleased to announce the engagement of nanoComposix Inc. ("nanoComposix") to complete the...
2020-10-21 7:15 PM EDT
Therma Bright und Orpheus Medica sichern Mitacs-Finanzierung zur Unterstützung ihres Forschungs- und Entwicklungsprogramms für COVID-19
Toronto, Ontario--(Newsfile Corp. - Freitag, 9. Oktober 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" oder das "Unternehmen"), ein fortschrittliches Medizintechnikunternehmen, und sein Mitentwicklungspartner, Orpheus Medica Inc. ("Orpheus") freuen sich über die Bewilligung eines "Mitacs Elevate"-Forschungspraktikumsprogramms. Der Projektantrag unterlief eine Peer-Review. Ende September wurden Matching-Mittel für ein Postdoktorandenstipendium bewilligt. Therma und Orpheus führen derzeit...
2020-10-09 10:20 AM EDT
Therma Bright and Orpheus Medica Secure Mitacs Funding to Support Its COVID-19 Research and Development Program
Toronto, Ontario--(Newsfile Corp. - October 8, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, and its co-development partner, Orpheus Medica Inc. ("Orpheus") are pleased to announce the recent award of a Mitacs Elevate research internship program . The project proposal has been peer-reviewed and approved in late September for matching funds for a Postdoctoral Fellowship. Therma and Orpheus are conducting feasibility...
2020-10-08 9:05 AM EDT
Therma Bright & Orpheus Medica to be Featured on BTV Business Television on BNN Bloomberg
Toronto, Ontario--(Newsfile Corp. - September 23, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, and its co-development partner, Orpheus Medica Inc. ("Orpheus") are pleased to announce they will be appearing on National TV on Saturday September 26 and Sunday September 27, 2020. The interview will focus on Therma's products and CoviSafeTM, a rapid test for detecting SARS-CoV-2 in saliva. BTV-Business Television is Canada's...
2020-09-23 7:00 AM EDT
Therma Bright and Orpheus Provide Development Update for its COVID-19 Rapid Saliva Test, CoviSafe(TM)
Toronto, Ontario--(Newsfile Corp. - September 15, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, and its co-development partner, Orpheus Medica Inc. ("Orpheus") are pleased to provide an update on the development progress of the CoviSafeTM rapid test for detecting SARS-CoV-2 in saliva. As announced on September 3, 2020, Orpheus identified a series of polypeptides for the screening and detection of the virus (SARS-CoV-2)...
2020-09-15 5:00 AM EDT
Therma Bright und Orpheus identifizieren neue biologische Nachweismoleküle für den COVID-19-Schnelltest
Toronto, Ontario--(Newsfile Corp. - Freitag, 4. September 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" oder das "Unternehmen"), ein fortschrittliches Technologieunternehmen für medizinische Geräte, freut sich bekannt zu geben, dass sein Entwicklungspartner Orpheus Medica Inc. ("Orpheus") eine Reihe von Polypeptiden für das Screening und den Nachweis des COVID-19 verursachenden Virus (SARS-CoV-2) identifiziert hat. Die von Orpheus und seinen akademischen Mitarbeitern durchgeführten...
2020-09-04 9:18 AM EDT
Therma Bright and Orpheus Identify Novel Biological Detection Molecules for COVID-19 Rapid Test
Toronto, Ontario--(Newsfile Corp. - September 3, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that its co-development partner, Orpheus Medica Inc. ("Orpheus") has identified a series of polypeptides for the screening and detection of the virus (SARS-CoV-2) causing COVID-19. The research carried out by Orpheus and its academic collaborators has resulted in several high-quality polypeptides that...
2020-09-03 8:58 AM EDT
Therma Bright Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - September 1, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, provides updates on the following: Further Testing of TherOZap® Technology Against the Dengue Virus; Redesign of InterceptCS™ Cold Sore Technology; Relaunch of BenePod® and Venowave® products; Joint development with Orpheus - CoviSafe™. Therma Bright Plans Further Testing of TherOZap® Technology Against the Dengue Virus As...
2020-09-01 9:25 AM EDT
Therma Bright schließt eine Vereinbarung mit Orpheus zur gemeinsamen Entwicklung des COVID-19 Speichel-Schnelltests von Orpheus Medica, CoviSafe(TM)
Toronto, Ontario--(Newsfile Corp. - Freitag, 28. August 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" oder das "Unternehmen"), ein fortschrittliches Medizintechnikunternehmen, freut sich bekannt zu geben, eine endgültige Vereinbarung zur gemeinsamen Entwicklung mit Orpheus Medica Inc. ("Orpheus") oder (Therma & Orpheus, die "Parteien") unterzeichnet zu haben. Diese Vereinbarung eröffnet Therma Zugang zu der neuen biologischen Plattform von Orpheus und ermöglicht die gemeinsame Entwicklung...
2020-08-28 9:01 AM EDT
Therma Bright Enters into Co-Development Agreement with Orpheus Medica's COVID-19 Rapid Saliva Test, CoviSafe(TM)
Toronto, Ontario--(Newsfile Corp. - August 27, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that it has signed a co-development definitive agreement with Orpheus Medica Inc. ("Orpheus") or (Therma & Orpheus, the "Parties"). This agreement will allow Therma access to Orpheus' novel biological platform and the joint development of a rapid saliva test for the screening and detection of the virus...
2020-08-27 9:07 AM EDT
Therma Bright Acquires Benepod(R) Pain Relief Technology and Other Innovative Medical Device Technology from Saringer Life Science Technologies Inc.
Toronto, Ontario--(Newsfile Corp. - August 26, 2020) - Therma Bright Inc. (TSXV: THRM), ("Therma Bright" or the "Company"), a progressive medical device technology company, is pleased to announce that it has closed the transaction to acquire Benepod® pain relief technology and other innovative medical device technology from Saringer Life Science Technologies Inc. ("Saringer" or "SLST Inc."). After completion of final negotiations, Therma acquired the Saringer assets in an all cash transaction...
2020-08-26 5:00 AM EDT
Update von Therma Bright zu den Transaktionen Saringer und Orpheus
Toronto, Ontario--(Newsfile Corp. - Donnerstag, 20. August 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" oder das "Unternehmen"), ein fortschrittliches Medizingeräteunternehmen, gibt hiermit ein Update in Erwiderung auf Anfragen von Aktionären. Saringer - Akquise von Vermögenswerten (Benepod®-Schmerzlinderungstechnologie) Wie bereits zuvor angekündigt (siehe Pressemitteilungen vom 15. Januar, 8. April und 9. Juli 2020), hat Therma eine zufriedenstellende Due Diligence-Prüfung...
2020-08-20 4:17 PM EDT
Therma Bright Provides Corporate Update on the Saringer and Orpheus Transactions
Toronto, Ontario--(Newsfile Corp. - August 20, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, provides this corporate update in response to inquiries from shareholders. Saringer - Asset Acquisition (Benepod® pain relief technology) As previously announced (refer to news releases of January 15, April 8 & July 9, 2020), Therma has completed satisfactory due diligence and intends to acquire Benepod® pain relief technology and...
2020-08-20 5:00 AM EDT
Therma Bright Schließt Die Due-Diligence-Prüfung des COVID-19-Speichelschnelltests CoviSafe(TM) von Orpheus Medica Ab Und Geht in Phase 2 über
Toronto, Ontario--(Newsfile Corp. - Freitag, 14. August 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" oder das "Unternehmen"), ein fortschrittliches Medizintechnikunternehmen, freut sich bekannt zu geben, dass es die erste Phase seiner Due Diligence-Prüfung für die Plattformtechnologie von Orpheus Medica ("Orpheus") abgeschlossen hat und die Entwicklung eines Speichelschnelltests (CoviSafe™) zum Nachweis des Virus (SARS-CoV-2), das COVID-19 verursacht, plant. CoviSafe™ wird die neuartigen...
2020-08-14 12:00 AM EDT
Therma Bright Completes Due Diligence of Orpheus Medica's CoviSafe(TM) COVID-19 Rapid Saliva Test and Moves to Phase 2
Toronto, Ontario--(Newsfile Corp. - August 13, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that it has completed its Phase 1 due diligence on Orpheus Medica's ("Orpheus") platform technology and plan for the development of a rapid saliva test (CoviSafe™) for the detection of the virus (SARS-CoV-2) causing COVID-19. CoviSafe™ will integrate Orpheus' novel biologics and advanced computational...
2020-08-13 5:00 AM EDT
Therma Bright Announces Closing of Over-Subscribed Private Placement for $1,250,000
Toronto, Ontario--(Newsfile Corp. - August 6, 2020) - Therma Bright Inc. (TSXV: THRM), ("Therma" or the "Company"), a progressive medical device technology company, announces that it has completed the closing of its non-brokered private placement (the "Offering") previously announced on July 20, 2020 and increased July 22, 2020. The Company has issued 16,666,667 units for gross proceeds of $1,250,000. No finder's fee was paid in conjunction with the Offering. All securities issued are subject...
2020-08-06 4:00 PM EDT
Therma Bright Inc. Unaware of Any Material Change
Toronto, Ontario--(Newsfile Corp. - July 24, 2020) - Therma Bright Inc. (TSXV: THRM), ("Therma" or the "Company"), at the request of IIROC, Therma Bright Inc. wishes to confirm that the Company's management is unaware of any material change in the Company's operations that would account for the recent increase in market activity. About Therma Bright Inc. Therma Bright is a progressive medical device technology company focused on providing consumers and medical professionals with quality...
2020-07-24 3:26 PM EDT
Therma Bright Increases Private Placement to $1,250,000 Due to Increased Demand
Toronto, Ontario--(Newsfile Corp. - July 22, 2020) - Therma Bright Inc. (TSXV: THRM) ("Therma" or the "Company"), a progressive medical device technology company, is pleased to announce that further to its news release of July 20, 2020, it has received interest above the previously announced private placement of up to 13,333,334 units at a price of $0.075 per Unit for gross proceeds of up to $1,000,000. Accordingly, the Company intends to increase the amount to be raised under its...
2020-07-22 6:00 AM EDT